S2 E5.1 After the FDA Webcast: Beginning and Ending Perceptions

S2 E5.1 After the FDA Webcast: Beginning and Ending Perceptions
The Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspectives on the FDA Webcast, both before and after the group's detailed conversation

The panel shared overall impressions and key takeaways from the FDA webcast on NASH Drug Development, both before and after the detailed discussion. Key issues included the agency’s continued reliance on histology coupled with a willingness to accept digital pathology results, the importance of risk: benefit ratio in drug evaluation, the importance of a composite fibrosis+steatosis endpoint, and new approaches to clinical trials for cirrhosis.

Experience Nudge Learning! Interested in a new way of learning?